Connect
MJA
MJA

Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis

Serge Lubicz
Med J Aust 2005; 182 (7): 365-368.
Published online: 4 April 2005

To the Editor: The article by Baker et al was a timely review of managing anticoagulation therapy and balancing the risks of thrombosis and bleeding.1 However, in managing anticoagulation therapy before non-cardiac surgery in patients with mechanical cardiac valve prostheses, the suggested 5-day cessation of warfarin therapy, with only subcutaneous heparin cover, is not appropriate. I have had three patients with mechanical bileaflet mitral prostheses develop valve thrombosis while under this protocol, two with a fatal outcome. I have also had one patient with a mechanical bileaflet aortic valve develop a popliteal arterial embolus requiring thrombectomy, despite being treated according to the protocol.

  • Serge Lubicz

  • Suite 6.5, Victorian Heart Centre, Epworth Hospital, 89 Bridge Road, Richmond, VIC 3121.

Correspondence: 

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.